440 related articles for article (PubMed ID: 15983290)
41. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
[TBL] [Abstract][Full Text] [Related]
42. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
Kjeldsen SE; Julius S; Mancia G; McInnes GT; Hua T; Weber MA; Coca A; Ekman S; Girerd X; Jamerson K; Larochelle P; MacDonald TM; Schmieder RE; Schork MA; Stolt P; Viskoper R; Widimský J; Zanchetti A;
J Hypertens; 2006 Jul; 24(7):1405-12. PubMed ID: 16794491
[TBL] [Abstract][Full Text] [Related]
43. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Davis BR; Kostis JB; Simpson LM; Black HR; Cushman WC; Einhorn PT; Farber MA; Ford CE; Levy D; Massie BM; Nawaz S;
Circulation; 2008 Nov; 118(22):2259-67. PubMed ID: 19001024
[TBL] [Abstract][Full Text] [Related]
44. Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy.
Kearney-Schwartz A; Virion JM; Stoltz JF; Drouin P; Zannad F
Fundam Clin Pharmacol; 2007 Aug; 21(4):387-96. PubMed ID: 17635177
[TBL] [Abstract][Full Text] [Related]
45. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.
Irvin MR; Lynch AI; Kabagambe EK; Tiwari HK; Barzilay JI; Eckfeldt JH; Boerwinkle E; Davis BR; Ford CE; Arnett DK
J Hypertens; 2010 Oct; 28(10):2076-83. PubMed ID: 20577119
[TBL] [Abstract][Full Text] [Related]
46. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
47. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
Cushman WC; Ford CE; Cutler JA; Margolis KL; Davis BR; Grimm RH; Black HR; Hamilton BP; Holland J; Nwachuku C; Papademetriou V; Probstfield J; Wright JT; Alderman MH; Weiss RJ; Piller L; Bettencourt J; Walsh SM;
J Clin Hypertens (Greenwich); 2002; 4(6):393-404. PubMed ID: 12461301
[TBL] [Abstract][Full Text] [Related]
48. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
Proschan M; Ford CE; Cutler JA; Graumlich JF; Pavlik V; Cushman WC; Davis BR; Alderman MH; Gordon D; Furberg CD; Franklin SS; Blumenthal SS; Castaldo RS; Preston RA;
Stat Med; 2013 Feb; 32(5):884-97. PubMed ID: 22961832
[TBL] [Abstract][Full Text] [Related]
49. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
Piller LB; Simpson LM; Baraniuk S; Habib GB; Rahman M; Basile JN; Dart RA; Ellsworth AJ; Fendley H; Probstfield JL; Whelton PK; Davis BR;
J Gen Intern Med; 2014 Nov; 29(11):1475-83. PubMed ID: 25002161
[TBL] [Abstract][Full Text] [Related]
50. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
[TBL] [Abstract][Full Text] [Related]
51. Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension.
Heckman GA; Psaty BM
ACP J Club; 2003; 139(3):A15; author reply A15. PubMed ID: 14594435
[No Abstract] [Full Text] [Related]
52. [Correction of endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus during combined antihypertensive therapy].
Statsenko ME; Derevianchenko MV
Ter Arkh; 2014; 86(8):90-3. PubMed ID: 25306751
[TBL] [Abstract][Full Text] [Related]
53. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Cushman WC; Ford CE; Einhorn PT; Wright JT; Preston RA; Davis BR; Basile JN; Whelton PK; Weiss RJ; Bastien A; Courtney DL; Hamilton BP; Kirchner K; Louis GT; Retta TM; Vidt DG;
J Clin Hypertens (Greenwich); 2008 Oct; 10(10):751-60. PubMed ID: 19090876
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
JAMA; 2008 Jan; 299(3):296-307. PubMed ID: 18212314
[TBL] [Abstract][Full Text] [Related]
55. Diuretics are better first-line antihypertensive therapy than calcium channel blockers and ACE inhibitors.
Rollins G
Rep Med Guidel Outcomes Res; 2003 Jan; 14(2):5-7. PubMed ID: 12776699
[No Abstract] [Full Text] [Related]
56. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
Wright JT; Probstfield JL; Cushman WC; Pressel SL; Cutler JA; Davis BR; Einhorn PT; Rahman M; Whelton PK; Ford CE; Haywood LJ; Margolis KL; Oparil S; Black HR; Alderman MH;
Arch Intern Med; 2009 May; 169(9):832-42. PubMed ID: 19433694
[TBL] [Abstract][Full Text] [Related]
57. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
Xie F; Petitti DB; Chen W
Am J Hypertens; 2005 Apr; 18(4 Pt 1):464-9. PubMed ID: 15831354
[TBL] [Abstract][Full Text] [Related]
58. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Cushman WC; Davis BR; Pressel SL; Cutler JA; Einhorn PT; Ford CE; Oparil S; Probstfield JL; Whelton PK; Wright JT; Alderman MH; Basile JN; Black HR; Grimm RH; Hamilton BP; Haywood LJ; Ong ST; Piller LB; Simpson LM; Stanford C; Weiss RJ;
J Clin Hypertens (Greenwich); 2012 Jan; 14(1):20-31. PubMed ID: 22235820
[TBL] [Abstract][Full Text] [Related]
59. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Haywood LJ; Davis BR; Piller LB; Simpson LM; Ghosh A; Einhorn PT; Ford CE; Probstfield JL; Soliman EZ; Wright JT;
J Natl Med Assoc; 2018 Aug; 110(4):343-351. PubMed ID: 30126559
[TBL] [Abstract][Full Text] [Related]
60. Lack of effect of short-term treatment with amlodipine and lisinopril on retinal autoregulation in normotensive patients with type 1 diabetes and mild diabetic retinopathy.
Mehlsen J; Jeppesen P; Erlandsen M; Poulsen PL; Bek T
Acta Ophthalmol; 2011 Dec; 89(8):764-8. PubMed ID: 20346089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
